Skip to main content
Top
Published in: Digestive Diseases and Sciences 3/2007

01-03-2007 | Original Paper

Effects of Combination Therapy with Direct Hemoperfusion Using Polymyxin B-Immobilized Fiber and Oral Vancomycin on Fulminant Pseudomembranous Colitis with Septic Shock

Authors: Yoshihide Kimura, Koichi Sato, Hiroshi Tokuda, Naka Nakamura, Yasuaki Dohi, Etsuro Orito, Masashi Mizokami

Published in: Digestive Diseases and Sciences | Issue 3/2007

Login to get access

Abstract

We report 2 cases of fulminant pseudomembranous colitis with septic shock. The first case showed few symptoms, whereas the second case showed recurrence. Both cases rapidly developed shock and blood pressure was uncontrollable except with the use of pressor agents. Direct hemoperfusion using polymyxin B-immobilized fiber, which was previously demonstrated to have excellent therapeutic effects for the treatment of hypotension in septic shock by removing circulating lipopolysaccharide and oral vancomycin dramatically improved both cases’ clinical status and decreased their APACHE II scores (from 18 to 8 and from 16 to 9 points, respectively). Therefore, we suggest that direct hemoperfusion using polymyxin B-immobilized fiber improved hypotension-correcting cytokine balance with adsorption of endogenous cannabinoids in serum. Although colectomy is often performed to treat fulminant pseudomembranous colitis with septic shock, direct hemoperfusion can be easily performed with little risk to the patient. These cases strongly indicated that our combination therapy provides an important treatment for fulminant pseudomembranous colitis with septic shock.
Literature
1.
go back to reference Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB (1978) Antibiotics-associated pseudomembranous colitis due to toxin-producing Clostridia. N Engl J Med 298:531–534PubMedCrossRef Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB (1978) Antibiotics-associated pseudomembranous colitis due to toxin-producing Clostridia. N Engl J Med 298:531–534PubMedCrossRef
2.
go back to reference Fekety R, McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan ME (1997) Recurrent Clostridium difficile diarrhea. Characteristics of and risk factors for patients enrolled in prospective, randomized, double-blinded trial. Clin Infect Dis 24:324–333PubMed Fekety R, McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan ME (1997) Recurrent Clostridium difficile diarrhea. Characteristics of and risk factors for patients enrolled in prospective, randomized, double-blinded trial. Clin Infect Dis 24:324–333PubMed
3.
go back to reference Knaus WA, Draper EA, Wagner DP, Zimmerman JE (1985) APACHE II: a severity of disease classification system. Crit Care Med 13:818–829PubMedCrossRef Knaus WA, Draper EA, Wagner DP, Zimmerman JE (1985) APACHE II: a severity of disease classification system. Crit Care Med 13:818–829PubMedCrossRef
4.
go back to reference Farrell RJ, LaMont JT (2000) Pathogenesis and clinical manifestations of Clostridium difficile diarrhea and colitis. Curr Top Microbiol Immun 26:416–421 Farrell RJ, LaMont JT (2000) Pathogenesis and clinical manifestations of Clostridium difficile diarrhea and colitis. Curr Top Microbiol Immun 26:416–421
5.
go back to reference Klingler PJ, Metzger PP, Seelig MH, Pettit PD, Knudsen JM, Alvarez SA (2000) Clostridium difficile infection: risk factors, medical and surgical management. Dig Dis 18:147–160PubMedCrossRef Klingler PJ, Metzger PP, Seelig MH, Pettit PD, Knudsen JM, Alvarez SA (2000) Clostridium difficile infection: risk factors, medical and surgical management. Dig Dis 18:147–160PubMedCrossRef
6.
go back to reference Dallal RM, Harbrecht BG, Boujoukas AJ, Sirio CA, Farkas LM, Lee KK, Simmons RL (2002) Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 235:363–372PubMedCrossRef Dallal RM, Harbrecht BG, Boujoukas AJ, Sirio CA, Farkas LM, Lee KK, Simmons RL (2002) Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 235:363–372PubMedCrossRef
7.
go back to reference Palmer JD, Rifkind D (1974) Neutralization of the hemodynamic effects of endotoxin by polymyxin B. Surg Gynecol Obstet 138:755–759PubMed Palmer JD, Rifkind D (1974) Neutralization of the hemodynamic effects of endotoxin by polymyxin B. Surg Gynecol Obstet 138:755–759PubMed
8.
go back to reference Aoki H, Kodama M, Tani T, Hanasawa K (1994) Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber. Am J Surg 167:412–417PubMedCrossRef Aoki H, Kodama M, Tani T, Hanasawa K (1994) Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber. Am J Surg 167:412–417PubMedCrossRef
9.
go back to reference Varga K, Lake KD, Huangfu D, Guyenet PG, Kunos G (1996) Mechanism of the hypotensive action of anandamide in anesthetized rats. Hypertension 28:682–686PubMed Varga K, Lake KD, Huangfu D, Guyenet PG, Kunos G (1996) Mechanism of the hypotensive action of anandamide in anesthetized rats. Hypertension 28:682–686PubMed
10.
go back to reference Varga K, Wagner JA, Bridgen DT, Kunos G (1998) Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 12:1035–1044PubMed Varga K, Wagner JA, Bridgen DT, Kunos G (1998) Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 12:1035–1044PubMed
11.
12.
go back to reference Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, Takeda K, Akira S (1999) Differential roles of TLR 2 and TLR 4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 11:443–451PubMedCrossRef Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, Takeda K, Akira S (1999) Differential roles of TLR 2 and TLR 4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 11:443–451PubMedCrossRef
13.
go back to reference Klein TW, Lane B, Newton CA, Friedman H (2000) The cannabinoid system and cytokine network. Proc Soc Exp Biol Med 225:1–8PubMedCrossRef Klein TW, Lane B, Newton CA, Friedman H (2000) The cannabinoid system and cytokine network. Proc Soc Exp Biol Med 225:1–8PubMedCrossRef
14.
go back to reference Wang Y, Liu Y, Sarker KP, Nakashima M, Serizawa T, Kishida A, Akashi M, Nakata M, Kitajima I, Maruyama I (2000) Polymyxin B binds to anandamide and inhibits its cytotoxic effect. FEBS Letters 470:151–155PubMedCrossRef Wang Y, Liu Y, Sarker KP, Nakashima M, Serizawa T, Kishida A, Akashi M, Nakata M, Kitajima I, Maruyama I (2000) Polymyxin B binds to anandamide and inhibits its cytotoxic effect. FEBS Letters 470:151–155PubMedCrossRef
15.
go back to reference Hecht G, Pothoulakis C, LaMont JT, Madara JL (1998) Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayers. J Clin Invest 82:1516–1524CrossRef Hecht G, Pothoulakis C, LaMont JT, Madara JL (1998) Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayers. J Clin Invest 82:1516–1524CrossRef
Metadata
Title
Effects of Combination Therapy with Direct Hemoperfusion Using Polymyxin B-Immobilized Fiber and Oral Vancomycin on Fulminant Pseudomembranous Colitis with Septic Shock
Authors
Yoshihide Kimura
Koichi Sato
Hiroshi Tokuda
Naka Nakamura
Yasuaki Dohi
Etsuro Orito
Masashi Mizokami
Publication date
01-03-2007
Published in
Digestive Diseases and Sciences / Issue 3/2007
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-006-9494-5

Other articles of this Issue 3/2007

Digestive Diseases and Sciences 3/2007 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.